Literature DB >> 7962545

Antioxidant: a new role for RU-486 and related compounds.

S Parthasarathy1, A J Morales, A A Murphy.   

Abstract

RU-486 (17 beta-hydroxy-4-dimethylaminophenyl-17-alpha-propenyl estrone 4,9 diene-3-one; mifepristone) is suggested to act by binding to progesterone and glucocorticoid receptors. Based on its chemical nature, we anticipated that RU-486 may have potent antioxidant properties. We used the oxidation of LDL as our model system. RU-486 and a similar compound, onapristone, at 1-5-microM concentrations, decreased the formation of oxidized LDL. LDL isolated from plasma of subjects who were orally supplemented with RU-486 was resistant to oxidation, as compared to LDL isolated from control plasma. The antioxidant effect of RU-486 appears to reside in the dimethylaminophenyl side chain moiety. Reduction of the A-ring of the steroid molecule had no effect on its antioxidant property. Analogs of RU-486 which lack the dimethylaminophenyl group, were without antioxidant activity. Levonorgestrel, which lacks the dimethylaminophenyl group failed to inhibit the oxidation of LDL even at 100-microM levels. In contrast, ethinylestradiol and estradiol which do not possess the dimethylamino group, were able to inhibit the oxidation of LDL by virtue of their phenolic steroid "A" ring. Thus RU-486, with its long half life, high plasma concentrations, association with lipoproteins, and ability to readily enter the cell may have additional intra- and extra-cellular antioxidant effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962545      PMCID: PMC294624          DOI: 10.1172/JCI117551

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.

Authors:  S M Grunberg; M H Weiss; I M Spitz; J Ahmadi; A Sadun; C A Russell; L Lucci; L L Stevenson
Journal:  J Neurosurg       Date:  1991-06       Impact factor: 5.115

2.  Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes.

Authors:  F Jacolot; I Simon; Y Dreano; P Beaune; C Riche; F Berthou
Journal:  Biochem Pharmacol       Date:  1991-06-15       Impact factor: 5.858

3.  Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits.

Authors:  A Daugherty; B S Zweifel; G Schonfeld
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

4.  Determination of onapristone and its N-desmethyl metabolite in human plasma or serum by high-performance liquid chromatography.

Authors:  C Zurth; F Kagels
Journal:  J Chromatogr       Date:  1990-10-26

5.  Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells.

Authors:  S D Cushing; J A Berliner; A J Valente; M C Territo; M Navab; F Parhami; R Gerrity; C J Schwartz; A M Fogelman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

6.  Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B.

Authors:  S Ghosh; D Baltimore
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962

7.  Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate.

Authors:  F Parhami; Z T Fang; A M Fogelman; A Andalibi; M C Territo; J A Berliner
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Low density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis.

Authors:  S Parthasarathy; J C Khoo; E Miller; J Barnett; J L Witztum; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

9.  Treatment of breast cancer with different antiprogestins: preclinical and clinical studies.

Authors:  G H Bakker; B Setyono-Han; H Portengen; F H De Jong; J A Foekens; J G Klijn
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

10.  The antioxidant butylated hydroxytoluene protects against atherosclerosis.

Authors:  I Björkhem; A Henriksson-Freyschuss; O Breuer; U Diczfalusy; L Berglund; P Henriksson
Journal:  Arterioscler Thromb       Date:  1991 Jan-Feb
View more
  10 in total

1.  The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties.

Authors:  B Moosmann; C Behl
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 2.  Review of progress in sterol oxidations: 1987-1995.

Authors:  L L Smith
Journal:  Lipids       Date:  1996-05       Impact factor: 1.880

3.  Blocking stroke-induced immunodeficiency increases CNS antigen-specific autoreactivity but does not worsen functional outcome after experimental stroke.

Authors:  Christine Römer; Odilo Engel; Katarzyna Winek; Sonja Hochmeister; Tian Zhang; Georg Royl; Juliane Klehmet; Ulrich Dirnagl; Christian Meisel; Andreas Meisel
Journal:  J Neurosci       Date:  2015-05-20       Impact factor: 6.167

4.  The steroid RU486 induces UCP1 expression in brown adipocytes.

Authors:  Ana M Rodríguez; Andreu Palou
Journal:  Pflugers Arch       Date:  2004-08-27       Impact factor: 3.657

5.  Mifepristone (RU486) protects Purkinje cells from cell death in organotypic slice cultures of postnatal rat and mouse cerebellum.

Authors:  A M Ghoumari; I Dusart; M El-Etr; F Tronche; C Sotelo; M Schumacher; E-E Baulieu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-16       Impact factor: 11.205

6.  Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids.

Authors:  G Tiao; J Fagan; V Roegner; M Lieberman; J J Wang; J E Fischer; P O Hasselgren
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

7.  Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.

Authors:  Alicia A Goyeneche; Rubén W Carón; Carlos M Telleria
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

8.  Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.

Authors:  Chelsea R Tieszen; Alicia A Goyeneche; BreeAnn N Brandhagen; Casey T Ortbahn; Carlos M Telleria
Journal:  BMC Cancer       Date:  2011-05-27       Impact factor: 4.430

Review 9.  Antiprogestins in gynecological diseases.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reproduction       Date:  2014-09-24       Impact factor: 3.906

10.  A new role for RU486 (mifepristone): it protects sperm from premature capacitation during cryopreservation in buffalo.

Authors:  Jasmer Dalal; Pradeep Kumar; R K Chandolia; Shikha Pawaria; Rasika Rajendran; Suman Sheoran; Jerome Andonissamy; Dharmendra Kumar
Journal:  Sci Rep       Date:  2019-04-30       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.